Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy

B K Gundapaneni, M B Sultan, D J Keohane, J H Schwartz, B K Gundapaneni, M B Sultan, D J Keohane, J H Schwartz

Abstract

Background and purpose: To better characterize the effects of tafamidis in non-Val30Met patients with transthyretin familial amyloid polyneuropathy, this post hoc analysis compared the neurological results from a 12-month, open-label study of non-Val30Met versus Val30Met patients at month 12 from the 18-month, double-blind, placebo-controlled registration study. A baseline covariate adjusted analysis was used to control for differences in baseline neurological severity.

Methods: Neurological function was assessed using the Neuropathy Impairment Score - Lower Limbs (NIS-LL) in three cohorts: Val30Met tafamidis (n = 64), Val30Met placebo (n = 61) and non-Val30Met tafamidis (n = 21). The change in NIS-LL from baseline to month 12 for Val30Met and non-Val30Met tafamidis-treated patients was compared with the change from baseline at month 12 for Val30Met placebo-treated patients using a mixed-effects model for repeated measures (MMRM).

Results: The baseline adjusted mean (standard error) change in NIS-LL values at month 12 was similar for Val30Met [1.60 (0.78)] and non-Val30Met [1.62 (1.43)] tafamidis-treated patients and less than that observed in the Val30Met placebo-treated group [4.72 (0.77); P = 0.0055 for Val30Met and P = 0.0592 for non-Val30Met]. Based on the MMRM, the magnitude of change in both tafamidis-treated cohorts was similar across the range of observed baseline NIS-LL values, and was consistently less than that observed in the Val30Met placebo-treated group at month 12.

Conclusions: This baseline-adjusted analysis demonstrated that tafamidis treatment delayed neurological progression comparably in Val30Met and non-Val30Met patients across a range of baseline NIS-LL values. Neurological progression in these two genotype groups may be more similar than previously considered.

Trial registration: ClinicalTrials.gov NCT00409175 NCT00630864.

Keywords: Val30Met; amyloidosis; baseline severity; familial amyloid polyneuropathy; neurological progression; non-Val30Met; tafamidis; transthyretin.

© 2017 Pfizer. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Figures

Figure 1
Figure 1
Predicted LS mean NIS‐LL change from baseline to month 12 across a range of baseline NIS‐LL values in the intent‐to‐treat placebo and tafamidis cohorts. NIS‐LL, Neuropathy Impairment Score – Lower Limbs.

References

    1. Plante‐Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol 2014; 261: 1227–1233.
    1. Coelho T, Inês M, Concieção I, Saramago P, de Carvalho M, Costa J. Temporal trends in transthyretin familial amyloid polyneuropathy survival over a century. Int J Clin Neurosci Ment Health 2016; 3: P130.
    1. Mariani LL, Lozeron P, Theaudin M, et al Genotype−phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 2015; 78: 901–916.
    1. Coelho T, Maurer MS, Suhr OB. THAOS − the Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild‐type transthyretin amyloidosis. Curr Med Res Opin 2013; 29: 63–76.
    1. Sekijima Y, Yoshida K, Tokuda T, Ikeda S. of website. (accessed 13 March 2017)
    1. Coelho T, Waddington Cruz M, Fallet S, Carlsson M, Ong M‐L. The natural history of transthyretin familial amyloidosis polyneuropathy: an analysis from the Transthyretin Amyloidosis Outcomes Survey. Presented at the XV International Symposium on Amyloidosis; Uppsala: Sweden, 3–7 July 2016.
    1. Coelho T, Merlini G, Bulawa CE, et al Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther 2016; 5: 1–25.
    1. Coelho T, Maia LF, Martins da Silva A, et al Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785–792.
    1. Coelho T, Maia LF, Martins da Silva A, et al Long‐term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260: 2802–2814.
    1. Barroso FA, Judge DP, Ebede B, et al Long‐term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 2017; 24: 194–204.
    1. Ando Y, Sekijima Y, Obayashi K, et al Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR‐FAP) with Val30Met and non‐Val30Met: a phase III, open‐label study. J Neurol Sci 2016; 362: 266–271.
    1. Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long term (5.5 year) delay of neurologic progression in transthyretin familial amyloid polyneuropathy. Amyloid 2016; 23: 178–183.
    1. Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid 2017; 24: 30–36.
    1. Merlini G, Plante‐Bordeneuve V, Judge DP, et al Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non‐Val30Met transthyretin amyloidosis. Cardiovasc Transl Res 2013; 6: 1011–1020.
    1. Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR. Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 2017; 55: 323–332.
    1. Parman Y, Adams D, Obici L, et al Sixty years of transthyretin familial amyloid polyneuropathy (TTR‐FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR‐FAP. Curr Opin Neurol 2016; 29(Suppl. 1): S3–S13.
    1. Suhr OB, Larsson M, Ericzon BG, Wilczek HE. Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP World Transplant Registry. Transplantation 2016; 100: 373–381.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit